Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Q8PF
|
|||
| Former ID |
DIB011081
|
|||
| Drug Name |
Ad5f35-LMPd1-2-transduced autologous dendritic cells
|
|||
| Synonyms |
AddLMP1-I-LMP2; LMP1/LMP2 cytotoxic T-lymphocytes vaccine (nasopharyngeal cancer), Baylor College of Medicine; Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer); Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer),NCI
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Nasopharyngeal carcinoma [ICD-11: 2B6B; ICD-9: 147] | Investigative | [1] | |
| Company |
National Cancer Institute
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Epstein-Barr virus Latent membrane protein 1 (EBV LMP1) | Target Info | . | [1] |
| Epstein-Barr virus Latent membrane protein 2 (EBV LMP2) | Target Info | . | [1] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | CA patent application no. 876139, Nanotherapeutics for drug targeting. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.